

European Organisation for Research
and Treatment of Cancer
January 13, 2021

Title of the Clinical Trial: Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE"

Sponsor: European Organisation for Research and Treatment of Cancer (EORTC)

EORTC protocol number: 1762-STBSG

EudraCT number: 2018-002096-17

Protocol: version 2.0 dated 15 January 2020

Concerning: Premature end of trial.

Dear madam/sir,

After an extensive assessment of the study feasibility, it was decided to discontinue the above-mentioned trial on 30 September 2020 due to poor recruitment. Only two patients were enrolled in the whole study since the start of the trial (26 September 2019).

We would like to confirm that due to the lack of data collected and in order to protect anonymity of the two patients enrolled in the study, no results report will be generated.

Please note that all participating Investigators / sites have been informed about this premature end of trial by the sponsor.

Yours sincerely,
EORTC Headquarters

